119 related articles for article (PubMed ID: 15916502)
1. Raloxifene and colorectal cancer.
Walsh JM; Cheung AM; Yang D; Litwack S; Grady D
J Womens Health (Larchmt); 2005 May; 14(4):299-305. PubMed ID: 15916502
[TBL] [Abstract][Full Text] [Related]
2. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation.
Siris E; Adachi JD; Lu Y; Fuerst T; Crans GG; Wong M; Harper KD; Genant HK
Osteoporos Int; 2002 Nov; 13(11):907-13. PubMed ID: 12415439
[TBL] [Abstract][Full Text] [Related]
3. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
Martino S; Cauley JA; Barrett-Connor E; Powles TJ; Mershon J; Disch D; Secrest RJ; Cummings SR;
J Natl Cancer Inst; 2004 Dec; 96(23):1751-61. PubMed ID: 15572757
[TBL] [Abstract][Full Text] [Related]
4. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy.
Sarkar S; Mitlak BH; Wong M; Stock JL; Black DM; Harper KD
J Bone Miner Res; 2002 Jan; 17(1):1-10. PubMed ID: 11771654
[TBL] [Abstract][Full Text] [Related]
5. Raloxifene reduces risk of vertebral fractures [corrected] in postmenopausal women regardless of prior hormone therapy.
Johnell O; Cauley JA; Kulkarni PM; Wong M; Stock JL
J Fam Pract; 2004 Oct; 53(10):789-96. PubMed ID: 15469774
[TBL] [Abstract][Full Text] [Related]
6. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study.
Johnell O; Kanis JA; Black DM; Balogh A; Poor G; Sarkar S; Zhou C; Pavo I
J Bone Miner Res; 2004 May; 19(5):764-72. PubMed ID: 15068500
[TBL] [Abstract][Full Text] [Related]
7. Raloxifene: recent information on skeletal and non-skeletal effects.
Gluck O; Maricic M
Curr Opin Rheumatol; 2002 Jul; 14(4):429-32. PubMed ID: 12118180
[TBL] [Abstract][Full Text] [Related]
8. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis.
Maricic M; Adachi JD; Sarkar S; Wu W; Wong M; Harper KD
Arch Intern Med; 2002 May; 162(10):1140-3. PubMed ID: 12020184
[TBL] [Abstract][Full Text] [Related]
9. Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials.
Bouxsein ML; Chen P; Glass EV; Kallmes DF; Delmas PD; Mitlak BH
J Bone Joint Surg Am; 2009 Jun; 91(6):1329-38. PubMed ID: 19487509
[TBL] [Abstract][Full Text] [Related]
10. Can the prophylactic use of raloxifene, a selective estrogen-receptor modulator, prevent bone mineral loss and fractures in women with diagnosed osteoporosis or vertebral fractures?
Rosenfeld JA
West J Med; 2000 Sep; 173(3):186-8. PubMed ID: 10986186
[No Abstract] [Full Text] [Related]
11. [SERM & bone metabolism: protective effects of SERM against fracture risk and its long-term beneficial effects].
Inaba M
Clin Calcium; 2004 Oct; 14(10):27-31. PubMed ID: 15577128
[TBL] [Abstract][Full Text] [Related]
12. Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial.
Yaffe K; Krueger K; Cummings SR; Blackwell T; Henderson VW; Sarkar S; Ensrud K; Grady D
Am J Psychiatry; 2005 Apr; 162(4):683-90. PubMed ID: 15800139
[TBL] [Abstract][Full Text] [Related]
13. Bone histomorphometric and biochemical marker results of a 2-year placebo-controlled trial of raloxifene in postmenopausal women.
Ott SM; Oleksik A; Lu Y; Harper K; Lips P
J Bone Miner Res; 2002 Feb; 17(2):341-8. PubMed ID: 11811565
[TBL] [Abstract][Full Text] [Related]
14. Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial.
Barrett-Connor E; Cauley JA; Kulkarni PM; Sashegyi A; Cox DA; Geiger MJ
J Bone Miner Res; 2004 Aug; 19(8):1270-5. PubMed ID: 15231013
[TBL] [Abstract][Full Text] [Related]
15. Effect of raloxifene on sexual function in older postmenopausal women with osteoporosis.
Modugno F; Ness RB; Ewing S; Cauley JA
Obstet Gynecol; 2003 Feb; 101(2):353-61. PubMed ID: 12576261
[TBL] [Abstract][Full Text] [Related]
16. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
[TBL] [Abstract][Full Text] [Related]
17. The effect of raloxifene therapy on the risk of new clinical vertebral fractures at three and six months: a secondary analysis of the MORE trial.
Qu Y; Wong M; Thiebaud D; Stock JL
Curr Med Res Opin; 2005 Dec; 21(12):1955-9. PubMed ID: 16368046
[TBL] [Abstract][Full Text] [Related]
18. Raloxifene reduces vertebral fracture risk in postmenopausal women with osteoporosis.
Brandi ML
Clin Exp Rheumatol; 2000; 18(3):309-10. PubMed ID: 10895366
[No Abstract] [Full Text] [Related]
19. Safety assessment of raloxifene over eight years in a clinical trial setting.
Martino S; Disch D; Dowsett SA; Keech CA; Mershon JL
Curr Med Res Opin; 2005 Sep; 21(9):1441-52. PubMed ID: 16197663
[TBL] [Abstract][Full Text] [Related]
20. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.
Siris ES; Harris ST; Eastell R; Zanchetta JR; Goemaere S; Diez-Perez A; Stock JL; Song J; Qu Y; Kulkarni PM; Siddhanti SR; Wong M; Cummings SR;
J Bone Miner Res; 2005 Sep; 20(9):1514-24. PubMed ID: 16059623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]